A randomized controlled trial comparing autologous radiolabeled in vivo platelet (PLT) recoveries and survivals of 7‐day‐stored PLT‐rich plasma and buffy coat PLTs from the same subjects

Dumont, Larry J.; Dumont, Deborah F.; Unger, Zoe; Siegel, Alan; Szczepiórkowski, Zbigniew M.; Corson, Jill; Jones, Martin; Christoffel, Todd; Pellham, Esther; Bailey, S. Lawrence; Slichter, Sherrill J.

doi:10.1111/j.1537-2995.2010.03007.x

Cited by 22 publications

(16 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Overall, the results of storing BC PLTs in plasma or Plasmalyte were not different than storing PRP PLTs for similar times. These data are not different from those of other studies that compared radiolabeled autologous BC versus PRP PLTs in normal volunteers 4,18 and patients with thrombocytopenia. [19][20][21] These data suggest that BC PLTs would pass FDA licensing criteria for 6 days of storage and could be used in the United States interchangeably with PRP PCs.…”

Section: Discussioncontrasting

confidence: 65%

“…Because the PLTs are never hard centrifuged against the bottom of the bag but only against the red blood cell (RBC) layer, it has been assumed that the quality of BC PLTs would be better than PRP PLTs. However, when the same normal subjects donated whole blood on two separate occasions allowing a direct comparison of 7‐day‐stored PRP or BC PLTs from the two donations, there were no differences observed in the radiolabeled autologous PLT recoveries and survivals nor in the in vitro results between the two products …”

mentioning

confidence: 98%

“…However, when the same normal subjects donated whole blood on two separate occasions allowing a direct comparison of 7-day-stored PRP or BC PLTs from the two donations, there were no differences observed in the radiolabeled autologous PLT recoveries and survivals nor in the in vitro results between the two products. 4 We have previously reported the in vivo and in vitro results of extended stored PRP PCs stored in plasma or 80% Plasmalyte. 5 In this study, we report similar data for extended storage of BC PCs stored in plasma or Plasmalyte.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Extended storage of buffy coat platelet concentrates in plasma or a platelet additive solution

et al. 2014

Self Cite

View full text Add to dashboard Cite

Background Platelet concentrates prepared from whole blood in the U.S. are made using the platelet-rich-plasma (PRP) method. The platelet concentrates must be made within 8 hours of blood collection and stored for only 5 days. In Europe and Canada, platelet concentrates are made using the buffy-coat (BC) method from whole blood held overnight at 22°C and storage times may be up to 7 days. Our studies were designed to determine how long BC platelets can be stored in plasma or Plasmalyte while meeting the FDA’s post-storage viability criteria. Study Design, Materials, And Methods Normal subjects donated whole blood that was stored at 22°C for 22 ± 2 hours prior to preparation of BC platelets. Platelets were stored for 5 to 8 days in either plasma or Plasmalyte concentrations of 65% or 80%. Radiolabeled autologous stored versus fresh platelet recoveries and survivals were assessed as well as post-storage in vitro assays. Results BC platelets stored in either plasma or 65% Plasmalyte met FDA post-storage platelet recovery criteria for 7 days but survivals for only 6 days, while storage in 80% Plasmalyte gave very poor results. Both stored platelet recoveries and survivals correlated with the same donor’s fresh results, but the correlation was much stronger between recoveries than survivals. In vitro measures of extent of shape change, morphology score, and pH best predicted post-storage platelet recoveries, while annexin V binding best predicted platelet survivals. Conclusion BC platelets stored in either plasma or 65% Plasmalyte meet FDA’s post-storage viability criteria for 6 days.

show abstract

Section: Discussioncontrasting

confidence: 65%

mentioning

confidence: 98%

mentioning

confidence: 99%

See 1 more Smart Citation

Extended storage of buffy coat platelet concentrates in plasma or a platelet additive solution

et al. 2014

Self Cite

View full text Add to dashboard Cite

show abstract

“…The most commonly used in vivo measurements are platelet recovery and survival following transfusion, as mandated by the FDA (66.7% recovery of the same subjects fresh platelets after 24 hours and 58% recovery of the same subject's fresh platelets) [136]. However, platelet components in routine clinical use can fail to meet these criteria, highlighting a need for alternative criteria that provide information regarding platelet function following transfusion [137–140]. Nonetheless, there are strong correlations between some in vitro measurements and platelet recovery and survival in vivo.…”

Section: Quality Of Platelet Concentratesmentioning

confidence: 99%

Quality Assessment of Established and Emerging Blood Components for Transfusion

Acker

Marks

Sheffield

2016

Journal of Blood Transfusion

View full text Add to dashboard Cite

Blood is donated either as whole blood, with subsequent component processing, or through the use of apheresis devices that extract one or more components and return the rest of the donation to the donor. Blood component therapy supplanted whole blood transfusion in industrialized countries in the middle of the twentieth century and remains the standard of care for the majority of patients receiving a transfusion. Traditionally, blood has been processed into three main blood products: red blood cell concentrates; platelet concentrates; and transfusable plasma. Ensuring that these products are of high quality and that they deliver their intended benefits to patients throughout their shelf-life is a complex task. Further complexity has been added with the development of products stored under nonstandard conditions or subjected to additional manufacturing steps (e.g., cryopreserved platelets, irradiated red cells, and lyophilized plasma). Here we review established and emerging methodologies for assessing blood product quality and address controversies and uncertainties in this thriving and active field of investigation.

show abstract

“…I n vivo recovery and survival of transfused platelets (PLTs) is usually measured by quantification of radioactively labeled PLTs. [1][2][3][4][5][6][7][8][9][10] The Biomedical Excellence for Safer Transfusion (BEST) Collaborative has recommended a standard procedure for radiolabeling of PLTs with indium-111 and chromium-51. 11 Shortages of the supply with radionuclides have more recently become a serious problem.…”

mentioning

confidence: 99%

Platelet recovery and survival measured in patients by quantitative polymerase chain reaction of mitochondrial DNA

Doescher¹,

Petershofen²,

Hertenstein

et al. 2014

Transfusion

View full text Add to dashboard Cite

show abstract

A randomized controlled trial comparing autologous radiolabeled in vivo platelet (PLT) recoveries and survivals of 7‐day‐stored PLT‐rich plasma and buffy coat PLTs from the same subjects

Abstract: We were unable to demonstrate that single-unit BC-PLTs stored for 7 days have superior poststorage viability compared to PRP-PLTs. Failure to meet the minimum FDA criteria for poststorage PLT viability raises questions regarding the acceptance thresholds of these metrics.

Cited by 22 publications

References 18 publications

Extended storage of buffy coat platelet concentrates in plasma or a platelet additive solution

Extended storage of buffy coat platelet concentrates in plasma or a platelet additive solution

Quality Assessment of Established and Emerging Blood Components for Transfusion

Platelet recovery and survival measured in patients by quantitative polymerase chain reaction of mitochondrial DNA

Contact Info

Product

Resources

About